Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
NEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.72 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)2.48M
Market Cap
$1.02B
Enterprise Value$1.18B
Total Cash (Recent Filing)$163.69M
Total Debt (Recent Filing)$411.76M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 11, 2025EPS Estimate
0.02Last Dividend Ex-Date
Dec 17, 2020Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding129,178,620
10 Day Avg. Volume2,083,052
30 Day Avg. Volume2,483,852
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue1.72
Enterprise Value/Gross Profit3.91
Enterprise Value/Ebitda-24.41
Forecast
1Y Price Target
$10.67Price Target Upside34.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Legal VictoryNEO announced that it had won a summary judgment in its RaDaR patent infringement case with Natera.
Market PositionShares of NeoGenomics are up over 25% in the pre-market, as the company announced it won a summary judgment in its patent infringement lawsuit against Natera.
Product LaunchNEO is now free to commercialize its RaDaR ST assay and has launched RaDaR ST to biopharma customers.
Bears Say
Financial PerformanceManagement lowered full-year guidance for revenue and Adjusted EBITDA after reporting worse than expected revenue and higher-than-expected special charges.
Launch DelaysA delay in the commercial launch of PanTracer™ Liquid Biopsy impacted the expected NGS revenue ramp.
Revenue GuidanceNEO shares are down on what turned out to be a larger than expected guide cut to FY25.
NeoGenomics News
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $4.72 and its highest was $19.11 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $1.02B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Nov 11, 2025 which is in 44 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Jul 29, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.023 by $0.007.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics pays a Notavailable dividend of $0.4 which represents an annual dividend yield of N/A. See more information on NeoGenomics dividends here
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.02.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 129,178,620 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.03 in its last earnings report, beating expectations of $0.023. Following the earnings report the stock price went down -18.731%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
NeoGenomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.67 (34.55% Upside)
$10.67 (34.55% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $212.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.3%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.83%
12-Months-Change
Fundamentals
Return on Equity
-11.76%
Trailing 12-Months
Asset Growth
-15.17%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NEO Company Deck
NEO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While the clinical segment showed robust growth and operational achievements, significant challenges in the nonclinical and pharma segments led to a downward revision of the full-year financial guidance. The company is taking steps to address these issues, but the immediate future appears cautious.View all NEO earnings summariesNEO Stock 12 Month Forecast
Average Price Target
$10.67
▲(34.55% Upside)
Technical Analysis
Ownership Overview
1.23% Insiders
32.60% Mutual Funds
28.40% Other Institutional Investors
13.02% Public Companies and
Individual Investors